

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/550,866
	Filing Date	September 23, 2005
	First Named Inventor	Dimitrios T. Drivas
	Group Art Unit	
Examiner Name		
Sheet 1 of 1	Attorney Docket No: MP-02	

US PATENT DOCUMENTS				
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PM	2005/0013799A1	1/2005	Skurkovich et al.	
	2005/0013800A1	1/2005	Skurkovich et al.	
	2003/0175290A1	9/2003	Renner et al.	
	6,403,782 B1	6/2002	Luster et al.	
	2002/0098523A1	7/2002	Vaughan et al.	
	6,093,405	7/2000	Zagury et al.	
	5,993,814	11/1999	Williams et al.	
	60/396,636		Bachmann et al.	
	60/331,045		Renner et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
PM	WO 04/096849 A2	11-11-2004	University of Manitoba and Manitoba Institute of Child Health		
	WO 03/082349 A1	10-09-2003	Mercia Pharma, LLC		
	WO 03/040164 A2	05-15-2003	Cytos Biotechnology AG		
	WO 02/056905 A2	07-25-2002	Cytos Biotechnology AG		
	WO 01/66754 A1	09-13-2001	Cambridge Antibody Technology Limited		
	WO 99/10534	03-04-1999	Center for Blood Research, Inc.		
	WO 95/07985	03-23-1995	National Heart & Lung Institute; Ludwig Institute for Cancer Research		

EXAMINER

Bunna Manki

DATE CONSIDERED

9/4/07

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 508. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/550,866
	Filing Date	September 23, 2005
	First Named Inventor	Dimitrios T. Drivas
	Group Art Unit	
	Examiner Name	
Sheet 2 of 2	Attorney Docket No: MP-02	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PM		JOSE, P.J., et al. <i>Eotaxin: Cloning of an Eosinophil Chemoattractant Cytokine and Increased mRNA Expression in Allergen-Challenged Guinea-Pig Lungs, Biochemical and Biophysical Research Communications</i> , November 1994, pages 788-794, Vol. 205, No. 1.	
		JOSE, P.J., et al. <i>Eotaxin: A Potent Eosinophil Chemoattractant Cytokine Detected in a Guinea Pig Model of Allergic Airways Inflammation, J. Exp. Med.</i> , March 1994, pages 881-887, Vol. 179.	
		GARCIA-ZEPEDA, E., et al. <i>Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia, Nature Medicine</i> , April 1996, pages 449-456, Vol. 2, No. 4.	
		HERTZ, M., et al. <i>Active Vaccination Against IL-5 Bypasses Immunological Tolerance and Ameliorates Experimental Asthma, Journal of Immunology</i> , October 2001, pages 3792-3799, Vol. 167, No. 7.	
		GUTIERREZ-RAMOS, J.C., et al. <i>Eotaxin: From an Eosinophilic Chemokine to a Major Regulator of Allergic Reactions, Immunology Today</i> , November 1999, pages 500-504, Vol. 20, No. 11.	
		PONATH, P.D., et al. <i>Cloning of the Human Eosinophil Chemoattractant, Eotaxin Expression, Receptor Binding, and Functional Suggest a Mechanism for the Selective Recruitment of Eosinophils, Journal of Clinical Investigation</i> , February 1996, pages 604-612, Vol. 97, No. 3.	
		TANNENBAUM, C.S., et al. <i>The CXC Chemokines IP-10 and Mig are Necessary for IL-12-Mediated Regression of the Mouse RENCA Tumor, Journal of Immunology</i> , July 1998, pages 927-932, Vol. 161, No. 2.	

EXAMINER

Prima Mery

DATE CONSIDERED

9/4/07

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language translation is attached

10/550866

PTO/SBDBA(08-03)

Approved for use through 07/01/2008. OMB 0851-0031
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	TBD
Filing Date	
First Named Inventor	Dimitrios T. Drivas
Group Art Unit	
Examiner Name	

SEP 2009

Sheet 1 of 2

Attorney Docket No: MP-02

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
P-M	2005/0013799A1	1/2005	Skurkovich et al.	
	2005/0013800A1	1/2005	Skurkovich et al.	
	2003/0175290A1	9/2003	Renner et al.	
	2002/0098523A1	7/2002	Vaughan et al.	
	6,403,782 B1	6/2002	Luster et al.	
	6,093,405	7/2000	Zagury et al.	
	5,993,814	11/1999	Williams et al.	
	60/396,636		Bachmann et al.	
	60/331,045		Renner et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ¹
P-M	WO 04/096849 A2	11-11-2004	University of Manitoba and Manitoba Institute of Child Health		
	WO 03/082349 A1	03-24-2003	Mercia Pharma, LLC		
	WO 03/040164 A2	05-15-2003	Cytos Biotechnology AG		
	WO 02/056905 A2	07-25-2002	Cytos Biotechnology AG		
	WO 01/66754 A1	09-13-2001	Cambridge Antibody Technology Limited		

EXAMINER

Penna Ment

DATE CONSIDERED

9/4/07

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

10/550866

PTO/SB/08A(08-03)

Approved for use through 07/31/2008. OMB 0651-0031
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	TB
Filing Date	
First Named Inventor	Dimitrios T. Drivas
Group Art Unit	
Examiner Name	

3C09 Rec'd PCT/PTO 23 SEP 2009

Sheet 2 of 2

Attorney Docket No: MP-02

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PM		JOSE, P.J., et al. <i>Eotaxin: Cloning of an Eosinophil Chemoattractant Cytokine and Increased mRNA Expression in Allergen-Challenged Guinea-Pig Lungs</i> , Biochemical and Biophysical Research Communications, November 1994, pages 788-794, Vol. 205, No. 1.	
		JOSE, P.J., et al. <i>Eotaxin: A Potent Eosinophil Chemoattractant Cytokine Detected in a Guinea Pig Model of Allergic Airways Inflammation</i> , J. Exp. Med., March 1994, pages 881-887, Vol. 179	
		GARCIA-ZEPEDA, E., et al. <i>Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia</i> , Nature Medicine, April 1996, pages 449-456, Vol. 2, No. 4.	

EXAMINER

Berna Muntz

DATE CONSIDERED

9/4/07

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached